The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations

Arthritis and Rheumatism

Volumn 42, Issue 9, 1999, Pages 1833-1842

  Vaishnaw, Akshay K ^a   Toubi, Elias ^b   Ohsako, Satomi ^c   Drappa, Jorn ^d   Buys, Saundra ^e   Estrada, Jaime ^f   Sitarz, Anneliese ^g   Zemel, Larry ^h   Chu, Jia Li ^d   Elkon, Keith B ^d,i  

^a BIOGEN   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Department of Obstetrics Gynecology   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g Columbia University ^*  (United States)

^h Farmington   (United States)

ⁱ WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; PHOSPHOLIPID ANTIBODY;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DEATH; CELL VIABILITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CYTOPENIA; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYPERGAMMAGLOBULINEMIA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MALE; MOUTH ULCER; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA;

ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHILD, PRESCHOOL; FAMILY HEALTH; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHATIC DISEASES; MALE; MUTATION; PEDIGREE; SYNDROME; T-LYMPHOCYTES;

EID: 0033509379     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199909)42:9<1833::AID-ANR7>3.0.CO;2-Q     Document Type: Article

References (34)

1. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967;70:891-9.
2. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. The Canale Smith syndrome: an inherited autoimmune disorder associated with defective lymphocyte apoptosis and mutations in the Fas gene. N Engl J Med 1996;335:1643-9.
3. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. Molecular basis for the apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999;103:355-63.
4. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome. Cell 1995;81: 935-46.
5. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268: 1347-9.
6. Cohen PL, Eisenberg RA. lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-69.
7. Vaishnaw AK, McNally JD, Elkon KB. Apoptosis in the rheumatic diseases. Arthritis Rheum 1997;40:1917-27.
8. Nagata S. Apoptosis by death factor. Cell 1997;58:355-65.
9. Schattner E, Elkon KB, Yoo DH, Tumang J, Crow MK, Friedman SM. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995;182:1557-65.
10. Dhein J, Walczak H, Bäumler C, Debatin K-M, Krammer PH. Autocrine T cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
11. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluoresceinlabeled annexin V. J Immunol Methods 1995;184:39-51.
12. Gharavi AE, Harris EN, Lockshin MD, Hughes GRV, Elkon KB. IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies in SLE. Ann Rheum Dis 1988;47:286-90.
13. Balow JE, Austin HA III. Renal disease in systemic lupus erythematosus. Rheum Dis Clin North Am 1988;14:117-33.
14. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 1998;16:261-92.
15. Lippman SM, Arnett FC, Conley CL, Ness PM, Meyers DA, Bias WB. Genetic factors predisposing to autoimmune diseases: autoimmune hemolytic anemia, chronic thrombocytopenic purpura, and systemic lupus erythematosus. Am J Med 1982;73:827-40.
16. Garrone P, Neidhardt E-M, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995;182:1265-73.
17. Theofilopoulos AN, Dixon F. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390.
18. Morse HC III, Roths JB, Davidson WF, Langdon WY, Fredrickson TN, Hartley JW. Abnormalities induced by the mutant gene, lpr: patterns of disease and expression of murine leukemia viruses in SJL/J mice homozygous and heterozygous for lpr. J Exp Med 1985;161:602-16.
19. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998;187:1825-38.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
21. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
22. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, et al. The APO-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-34.
23. Ohsako S, Hara M, Harigai M, Fukusawa C, Kashiwazaki S. Expression and function of Fas antigen and Bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994;73:109-14.
24. Kovacs B, Vassilopoulos D, Vogelgesang SA, Tsokos GC. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol 1996;81:293-302.
25. Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, Pisetsky DS. et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992;176:1645-56.
26. Wang Y, Nose M, Kamoto T, Nishimura M, Hiai H. Host modifier genes affect mouse autoimmunity induced by the lpr gene. Am J Pathol 1997;151:1791-8.
27. Vidai S, Kono DH, Theofilopoulos AN. Loci predisposing to autoimmunity in MRL-Faslpr and C57BL/6-Faslpr mice. J Clin Invest 1998;101:696-702.
28. Elkon KB, Marshak-Rothstein A. B cells in systemic autoimmune disease: recent insights from Fas-deficient mice and men. Curr Opin Immunol 1996;8:852-9.
29. Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM. Immunodeficiency Rev 1992;3:101-21.
30. Rosen FS. Autoimmunity and immunodeficiency disease. Ciba Found Symp 1987;129:135-48.
31. Kozono Y, Kotzin BL, Holers VM. Resting B cells from New Zealand black mice demonstrate a defect in apoptosis induction following surface IgM ligation. J Immunol 1996;156:4498-503.
32. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989; 143:103-12.
33. Orlinick JR, Vaishnaw AK, Elkon KB. Structure and function of Fas/Fas ligand. Int Rev Immunol. In press.
34. Zhou T, Edwards CK III, Yang P, Wang Z, Bluethmann H, Mountz JD. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor 1. J Immunol 1996;156:2661-5.